The Pneumetron
NEWSTOOLSINFRASTRUCTURE
Pneumetron.AI may speed up search for drugs to treat brain conditions
Share
Skip to article content
  1. Home
  2. ›
  3. News
  4. ›
  5. Science
  6. ›
  7. AI may speed up search for drugs to treat brain conditions
Science·May 22, 2026·Updated Nov 18

AI may speed up search for drugs to treat brain conditions

BY PNEUMETRON EDITORIAL|3 MIN READ · 532 WORDS3 MIN READ|
Tools
Share
Illustrative photo: medicine, pills, medication, laptop wallpaper
AI may speed up search for drugs to treat brain conditions

Scientists at the UK Dementia Research Institute in Edinburgh are using artificial intelligence to accelerate the search for neurological treatments by identifying whether existing drugs can be repurposed. By using algorithms to analyze patient data—including voice recordings, eye scans, and lab-grown brain cells—researchers aim to detect disease patterns and predict suitable medicines for conditions such as motor neurone disease (MND).

Researchers hope this technology will allow them to find effective treatments in years rather than decades. This effort is supported by trial participants like Steven Barrett, a former civil servant from Alloa, Scotland, who was diagnosed with MND 10 years ago. Barrett is participating in MND-SMART, a clinical trial that tests multiple drugs simultaneously against a control group, rather than testing a single drug against a placebo.

"MND is a horrible disease, it strips you of who you are," Barrett told the BBC. "It rips any sense of future that you may feel that you had planned for yourself - all that goes." Commenting on his participation in the trial, he added, "For me the research is much more than taking a tablet - it's taking a tablet with the intention of delivering outcomes, that may or may not help me but help others."

To power these trials, the institute is building a database of individuals with Parkinson's, Dementia, and MND. Clinicians collect iris scans and voice recordings, using AI to analyze the data for early indicators of future neurological issues. They also collect blood samples from volunteers to cultivate stem cells into groups of brain cells called neurones.

Pneumetron Intelligence Digest

Get AI intelligence briefings delivered daily.

Get our automated briefing — research signals, system dispatches, and deep science digests straight to your inbox.

Existing drugs are tested on these neurones using a combination of robotics, traditional laboratory equipment, and machine learning algorithms. These algorithms are trained to identify which of the approximately 1,500 approved drugs could convert a diseased neurological signature into a healthy one. Drugs identified by the AI can then proceed directly into clinical trials.

Institute chief executive Prof Siddarthan Chandran explained that redeploying approved drugs is more straightforward and faster than developing new formulas from scratch, which can take more than 10 years. "The brain is the most complicated organ in the body, so we've got to contend with the paradox of that complexity," Chandran told the BBC, noting that new technologies now allow researchers to perform work that was previously impossible.

This research aligns with other global efforts using AI to analyze medical data. Scientists at the Massachusetts Institute of Technology in the United States have used generative AI to identify novel antibiotic compounds for superbugs like gonorrhoea, as well as treatments for Parkinson's. Additionally, in 2024, Harvard University researchers developed a neural network model called TxGNN to identify existing drugs that could treat rare conditions.

The AI-driven search for treatments comes amid ongoing discussion over traditional drug development. A recent review of 17 studies involving 20,342 volunteers analyzed the Alzheimer's drugs lecanemab and donanemab, which remove amyloid protein from the brain. The review concluded that while the drugs slowed disease progression, the effect was not significant enough to make a meaningful difference to patients, a finding that drew backlash from other scientists. Despite these debates, Professor Chandran stated he remains confident that neurological research is "at the tipping point of change."

#artificial intelligence#uk dementia research institute#motor neurone disease#drug repurposing#siddarthan chandran
PE
PUBLISHED BY

PNEUMETRON EDITORIAL

Pneumetron's pipeline pairs AI-assisted drafting with human editorial review before publishing — our goal is to make staying informed easier, not to replace real reporting.

Source Material:bbc.com ↗
Share this article
Share
Stay Informed

Never miss a signal.

Subscribe to the Pneumetron Intelligence Digest.

Next →
SpaceX launches massive Starship V3 rocket on test flight

More from Science

View All →
ScienceSep 21
Illustrative photo: planner, hd wallpaper, wallpaper 4k, march

NASA Unveils Agenda for Ad ASTRA Community Workshop on Space Technology

NASA has released the comprehensive schedule and abstracts for the upcoming Ad ASTRA Community Workshop, a pivotal event focused on the future of space technology and exploration. The gathering aims to bridge the gap between theoretical research and practical implementation for deep space missions.

BY PNEUMETRON1 MIN READ
Read more
ScienceSep 20
Illustrative photo: ease, balance, easy, power

Yugap Wellness Expands Portfolio with Targeted Gut and Sleep Formulations

Yugap Wellness has introduced two new products, YuGut and YuSleep, aiming to capture growing market interest in evidence-based health supplements. This expansion marks a strategic shift for the company as it leans into the science-backed wellness sector.

BY PNEUMETRON1 MIN READ
Read more
ScienceSep 20
Illustrative photo: money, profit, finance, business

The Roar Returns: India’s Tiger Population Reaches 3,682

India has solidified its position as a global leader in wildlife preservation, with the latest census confirming a tiger population of 3,682. This milestone reflects the success of integrated science-based monitoring and deep-rooted community engagement strategies.

BY PNEUMETRON1 MIN READ
Read more
ScienceSep 19
Illustrative photo: padlock, lock, chain, key

KGK Science Secures Strategic Growth Capital from Maxim Partners

Contract research organization KGK Science has finalized a growth investment agreement with Maxim Partners to accelerate its expansion. This capital infusion aims to bolster the company's clinical trial capabilities and infrastructure within the nutraceutical and natural health product sectors.

BY PNEUMETRON1 MIN READ
Read more

Comments

Most Read

01
Science·Sep 21
NASA Unveils Agenda for Ad ASTRA Community Workshop on Space Technology
02
Science·Sep 5
NASA Refines 2026 Small Explorer Mission Solicitation with Program Amendment
03
Science·Aug 10
Shark-Mounted Sensors: A New Frontier in Hurricane Forecasting
04
Science·Aug 2
Breakthrough Results: New HIV Pill Completes First Human Trial
05
Science·Aug 28
The Linguistic Tax: How AI is Reshaping Scientific Communication for Non-Native Speakers
Daily Digest

Get top AI & tech signals delivered to your inbox every morning.

Subscribe →
Follow Signals
X / TWITTERLINKEDININSTAGRAMYOUTUBETELEGRAM

THE PNEUMETRON

The publication of modern technology, AI, and infrastructure.

AI-assisted, human-reviewed.

NEWS CATEGORIES

  • AI RESEARCH
  • TECHNOLOGY
  • WORLD
  • BUSINESS
  • POLITICS
  • SCIENCE
  • HEALTH
  • SPORTS
  • ENTERTAINMENT

AI & RESEARCH

  • AI RESEARCH
  • INFRASTRUCTURE
  • TOOLS
  • DEEP DIVES
  • TECHNICAL DISPATCHES

RESOURCES

  • ABOUT US
  • CONTACT
  • CAREERS
  • ADVERTISE
Pneumetron.
© 2026 Pneumetron. AI-assisted, human-reviewed.
All rights reserved.
ABOUTTOOLSPRIVACYTERMSCONTACT